Israel finally ends $10 billion binary options scam – or does it?
By Alison Weir | If Americans Knew | October 26, 2017
Israeli lawmakers have finally passed a law they say will ban Israel’s notorious binary options industry, which has brought in $10 billion a year.
The money was made by scamming millions of people around the world. A recent Reuters article reports: “London-based lawyers said hundreds of their clients were duped out of vast sums of money by some Israeli firms. More than 100 operators are estimated to be based in Israel, a technology hub.”
The industry was officially banned in the U.S. but Israeli operators still managed to scam many Americans. An article in Finance Feeds reports: “America is still a target for these nefarious entities whose methodology stems not from the financial markets or technology sectors, but from the lowbrow depths of online gambling, lead buying and affiliate marketing in Israel.”
News stories through the years have described misery and suicides among victims. Finally, a year ago the Israeli government banned sales of binary options to Israelis, but continued to permit them to the rest of the world.
The current bill that now also outlaws sales abroad was passed when Israeli legislators became concerned that the industry was hurting Israel’s image.
The Jewish Telegraphic Agency (JTA) reports that Knesset member Rachel Azaria said in introducing the recent bill: “We worry about the BDS movement. This industry has a huge impact on how Israel is viewed throughout the world. Our government officials go to international conferences and their colleagues abroad raise their eyebrows because of this industry.”
Israel National News reports that notes on behalf of the proposed legislation warned that “Israeli binary option companies risked damaging the country’s reputation and ‘could foment anti-Semitism’.”
The Times of Israel reports that the legislation was catalyzed by the outcry “among overseas law enforcement agencies, with the FBI at the forefront, that Israel was allowing this ‘monstrous’ fraud to flourish year after year.”
For years the Israeli government did little to stop it. JTA reports that despite widespread awareness of the scam, “Only a handful of Israelis have been arrested for binary options fraud, and none have been indicted, even as international law enforcement against the industry has ramped up.”
The article reports that an Israeli police superintendent “said Israeli organized crime was being massively enriched and strengthened because of law enforcement’s failure to grasp the scope of the problem.”
The law is set to take effect in three months, but some raise questions about it, charging that it lets perpetrators off the hook without punishment, allows scammers to simply relocate, and exempts similar activities, allowing the massive profits through victimization to continue.
The Times of Israel reports: “The original text was watered down — creating loopholes through which binary options and other rogues, simply by retooling what they do, will be able to continue to prosper.”
Austin Smith, founder of a company that reclaims money for binary options victims, calls the law “total garbage” that allows perpetrators to shift into new rackets without answering for their past scams.
“It’s more a political talking point than actually something with teeth that’s going to stop more fraud from being perpetrated,” he said. “It also does nothing to help victims of fraud recover any of their money.”
JTA reports that Smith is working with attorneys around the world to track down the heads of binary options companies as they open new operations in Cyprus and elsewhere, moving into such industries as diamond sales, cryptocurrencies and predatory business loans.
The original legislation authored by the Israel Securities Authority would have also outlawed similar gambits – companies involved in the foreign exchange market, or Forex, and CFD financial instruments. Pressure from lobbyists caused these to be removed from the bill.
Also, some actions are still permissible under the new law. Finance Magnates reports that binary options agents will be allowed “to provide research and development services (in other words – to develop the trading software) and to sell trading software as a shelf product.”
The FM article points out: “It remains to be seen how the amendment will be enforced.”
In particular, the question may be “how much flexibility the Israeli Securities Authority (ISA) will show when industry players, especially technology and platform solutions providers, seek relief or exemption from the ISA by trying to establish that their services do not amount to operating a trading platform but rather are in the permitted realm of software development.”
The Times of Israel reports: “Binary options owners and investors include former senior employees of the state, well-known public figures, relatives of former senior police officers and more. Immensely wealthy, some of the key figures make substantial charity donations — which in turn give them access to political figures all the way to the very top of the Israeli hierarchy.”
Past, present, and future problems
The Times of Israel, whose investigative journalists were instrumental in raising the alarm about binary options, reports that some elements of the back story to the current bill “raise extremely disturbing questions about the power of Israel’s criminal classes, the integrity of some of our legislators, and the quality of our law enforcement authorities.”
The article describes courageous actions by many Israelis intent on ending the scam. It also describes major failures and predicts deep problems for the future.
The article by David Horovitz, Why binary options ban is only a small victory in the war on Israeli corruption, is subtitled: “MKs finally moved this week to shut down a mega fraud. But the legislative process exposed the impotence of law enforcement… and the growing intimidatory power of Israel’s crooks.”
Following are some excerpts from Horovitz’s indepth report:
“The binary options crooks were barred from targeting Israelis in March 2016, but were being allowed to continue to steal from foreigners — and still are, in fact, because Monday’s law only goes into effect three months from now.”
“it quickly emerged that the police complaints bureaucracy is set up in such a way as to make it almost impossible for overseas victims of crime hatched in Israel to so much as report the matter.”
“when a Canadian father of four named Fred Turbide took his own life after an Israeli binary options firm stole all his money, and a clear paper trail established exactly who had defrauded him, the police did not take any action against the individuals and company involved, which continued to operate.”
“The fraudulent salespeople routinely conceal where they are located, misrepresent what they are selling and use false identities. (The FBI affidavit against Elbaz goes into considerable detail to explain the fraud, in all its miserable manifestations.)”
“The crooks are still out there. Some binary options firms have closed down. Others have relocated overseas, including to Cyprus and Ukraine. Some of the prime movers and shakers have already adjusted their focus to other fraudulent fields — in the fields of diamond sales, cryptocurrencies, initial coin offerings and predatory business loans.
“Top scammers are still enjoying the vast overseas bank accounts, the yachts, luxury cars, exotic holidays and other profits of their ill-gotten gains.”
“The ranks of binary options owners and investors include former senior employees of the state, well-known public figures, relatives of former senior police officers and more. Immensely wealthy, some of the key figures make substantial charity donations — which in turn give them access to political figures all the way to the very top of the Israeli hierarchy.
“They also donate to Jewish religious causes, for example Tel Aviv’s Great Synagogue, again with consequent friends in high places.”
“Some of those thousands of Israelis who have been drawn into lives of crime in the industry — cynical swindlers posing as financial experts and advisers, gloating at the naivety of their victims — are extremely cunning. And many of the higher-ups — including the computer coders, the lawyers, the affiliate marketers, and the SEO experts who manipulate Google and social media to ensure the prominence of seductive content hyping the ostensible potential for profit — are despicably smart. They will not go down without a fight. Israeli law enforcement seems largely disinclined even to try to tackle them, much less capable of doing so.”
“Monday night’s passage of the law banning binary options was but a small winning battle in what, to this extremely worried Israeli, looks for now like a losing war, a war Israel is barely bothering to fight, against a toxic cocktail of corruption.”
Alison Weir is executive director of If Americans Knew, president of the Council for the National Interest, and author of Against Our Better Judgment: The Hidden History of How the U.S. Was Used to Create Israel. Her upcoming book talks are listed here.
Single Payer and the Failure of Democrats in West Virginia
Morgan County USA | October 18, 2017
Congressman Alex Mooney is the former chair of the Republican Party in Maryland. But now he’s a congressman from the second Congressional district of West Virginia.
Talley Sergent
How did that happen? In 2014, Mooney saw that he wasn’t going to win anything in Maryland, so he crossed the bridge over the Potomac River and came on over to West Virginia.
Mooney should have been — and in 2018 should be — easily defeated. Mooney puts the interests of powerful out of state corporations over the interests of the people of his district. He is hardly ever seen in the district. (Instead, he does phone call town hall meetings.)
Aaron Scheinberg
Strike three and he should be out.
But he keeps winning.
Why?
Democrats in West Virginia are politically bankrupt.
Take for example the two declared Democratic candidates for the Mooney seat.
One is Talley Sergent. She’s a former public relations executive at Coca-Cola.
The other is Aaron Scheinberg. He has been endorsed by Congressman Seth Moulton of the New Democrat Coalition, a group that raises funds from Big Business and is seeking to move the Democratic Party to the right.
Both Sergent and Scheinberg refuse to take economic positions that would rile big business.

Both, for example, have refused to back the West Virginia Democratic Party platform’s call for a single payer, Medicare for All plan along the lines of HR 676.
HR 676 currently has 120 co-sponsors in the House of Representatives — none from West Virginia.
When asked about this, Scheinberg spokesperson Elizabeth Gale said that “Aaron believes that we have a duty to each other to ensure that all West Virginians have access to comprehensive health care.”
“As a veteran, Aaron is lucky to receive reliable, affordable health care through the VA,” Gale said. “He believes no one should to have to worry about losing or being denied health insurance. That will be a major focus of his agenda if he is elected. As far as commenting on specific bills, Aaron will wait until he can participate in the debate within Congress.”
But Margaret Flowers of Health Over Profit, said that the phrase “access to health care” is used by politicians across the spectrum to dodge the issue of single payer.
“Politicians will say that people have access to health care right now under the current system, it’s just that some people can’t afford it,” Flowers said. “Will Democrats say that a public option gives access to health care? The policies matter and candidates need to show that they understand what policies will solve the crises we face.”
“It is an unwillingness to take strong stances that is one of the reasons Democrats are doing so poorly. The majority of Democratic voters support single payer health care and it is a proven policy, so there is nothing controversial about supporting it. Voters are looking for candidates with the courage to take positions.”
While at Coca-Cola, Sergent worked to promote a Coca-Cola front group called the Global Energy Balance Network.
The message of the network? Exercise more and worry about calories less. Take the focus off of sugary drinks like Coke and put the focus on the couch potato behind the straw.
In August 2015, the New York Times exposed Coke’s front group in an article titled — Coca-Cola Funds Scientists Who Shift Blame for Obesity Away From Bad Diets.
The Times reported that Coca-Cola spent $1.5 million to start the organization.
“Health experts say this message [exercise more important than diet] is misleading and part of an effort by Coke to deflect criticism about the role sugary drinks have played in the spread of obesity and Type 2 diabetes,” the Times reported. “They contend that the company is using the new group to convince the public that physical activity can offset a bad diet despite evidence that exercise has only minimal impact on weight compared with what people consume.”
“This clash over the science of obesity comes in a period of rising efforts to tax sugary drinks, remove them from schools and stop companies from marketing them to children. In the last two decades, consumption of full-calorie sodas by the average American has dropped by 25 percent.”
“Coca-Cola’s sales are slipping, and there’s this huge political and public backlash against soda, with every major city trying to do something to curb consumption,” Michele Simon, a public health lawyer, told the Times. “This is a direct response to the ways that the company is losing. They’re desperate to stop the bleeding.”
One internal Coca-Cola email shows the head of Coke’s public relations department — Clyde Tuggle — reporting that “Talley has been leading some of our health and wellness work” and that “I’d like her to be my right hand and a core part of the team on this work going forward” — referring to the Global Energy Balance Network.
Gary Ruskin of the public interest group US Right to Know, which helped expose Global Energy Balance Network and make public the internal Coca-Cola emails, said that “Talley Sergent is perhaps the least qualified person in West Virginia to serve in Congress.”
“As a Coke public relations executive, Sergent helped perpetrate a deceit so egregious that it was exploded on the front page of the New York Times. She was a Coke handler for one of its front groups, the Global Energy Balance Network, and their efforts to snooker consumers and public health leaders, and to shield Coke from accountability for its role in helping to create the global obesity epidemic.”
“Now she wants to represent West Virginia in Congress. There is already enough deceit in Congress without her.”
“Coke’s role in West Virginia has been especially destructive of late. The state is suffering from some of the worst levels of obesity in the nation. In a notable insult to public health, the founding dean of the West Virginia University School of Public Health was a key Coke ally and a leader in Coke’s Global Energy Balance Network debacle. Gregory Hand left the deanship following the avalanche of negative news coverage about his role in the Coke deceit. And now comes Talley Sergent.”
Sergent now says it was a mistake for Coca-Cola to fund the Global Energy Balance Network and that after the Times article ran, she helped move Coca Cola into a new, more transparent direction.
In response to an inquiry, Sergent, a native of Huntington, West Virginia defended her work at Coca-Cola and took a barely veiled shot at Ruskin (based in Oakland, California), Scheinberg (who is originally from Cherry Hill, New Jersey) and Mooney (the former chair of the Republican Party in Maryland) as “outsiders.”
And Coca-Cola isn’t an outsider doing tremendous harm to the state?
“Isn’t West Virginia number one in obesity in the country?” Sergent was asked.
“We’re actually number two — behind Mississippi,” she said.
(Actually, according to a recent listing, West Virginia is number one — with a 37.7 percent obesity rate, with Mississippi coming in second with a 37.3 obesity rate.)
“Outsiders think they know voters here in West Virginia – shoot – we have folks from outside the state moving here just to run,” Sergent said. “But, like most West Virginians, I don’t take cues from special interests or outsiders, just the special people of my home state.”
“On my watch, the Coca-Cola Company transformed its approach to public health, owning up to its mistakes, becoming more transparent with its consumers and starting an open dialogue with the public health community. It wasn’t easy work but it was the right thing to do.”
“Now, I’m taking the same approach to Congress. We need a congresswoman who will take tough obstacles like health care head on, beginning with protecting and improving the Affordable Care Act, which will help break the cycle of opioid addiction, improve lives with preventive care and coverage for pre-existing conditions and encourage every West Virginian to live their best life. West Virginia needs a congresswoman who will stand up for the people and who welcomes an open dialogue with every West Virginian, no matter what. As congresswoman, I’ll do just that.”
But Sergent refused to commit to a public health campaign against sugary drinks or to a single payer, Medicare for All health program.
Some West Virginians aren’t giving up on Sergent or Scheinberg.
West Virginians Cathy Kunkel, Sally Roberts Wilson, and Lynn Moses Yellott, who are active members of grassroots organizations in the state advocating improved Medicare for All, have spoken with both Sergent and Scheinberg.
“We will continue to educate and push these candidates to support a single-payer Medicare for All system as the only real way to fix our broken healthcare system,” Kunkel, Wilson and Yellot said in a statement. “HR 676 is the only solution put forth that will enable the country to afford comprehensive care for everyone. We urge candidates to ask voters the question — ‘Since under expanded and improved Medicare for all, more than 95% of you will pay less through a fair tax than you now pay for premiums, co-pays, and deductibles, are you willing to convert the money you now pay for health insurance and out of pocket expenses to a fair tax so all in our country can have needed care?’ The grassroots will continue to educate and to push candidates to support National Improved Medicare for All.”
In addition to working for Coca-Cola, Sergent was the West Virginia director for Hillary Clinton’s 2016 campaign for President.
And unfortunately for the people of the second Congressional district, Sergent and Scheinberg appear to be playing by the same Clinton corporate playbook that brought us President Trump — and that will re-elect Congressman Mooney.
‘Permanent War Economy’: EU Defense Policy ‘Outsourced’ to Arms Industry
Sputnik – October 17, 2107
A report issued by Belgian campaign group Vredesactie (Peace Action) has documented how Europe’s defense industry played a pivotal role in the development of military strategies, with plans closely modeled on proposals made by major arms firms.
In 2016, the European Union took an unprecedented step, setting up the Preparatory Action on Defense Research — a military program worth US$1.05 billion — and proposing the establishment of a European Defense Fund, which allocates almost US$50 billion to the research, development and procurement of weapons over 10 years. While civil society, the academic world, and the European Parliament, were almost entirely excluded from policy discussions, the European arms industry left a “heavy footprint” in negotiations.
In essence, as the militarization of the 28-member bloc has accelerated rapidly, the arms industry has had access to every stage of decision-making processes, from setting agendas to drawing up the provisions of various action plans, Vredesactie has found.
“Rather than a reflection of what security means and how to ensure it, the European strategy is dominated by developing and selling new capabilities. Supporting the defense industry has become a goal in itself. Meanwhile, actual security challenges remain unanswered and mistakes from past policy choices perpetuated, at a high cost,” the report stated.
Over the course of their investigation, Vredesactie uncovered minutes of a 2015 meeting of the so-called Group of Personalities (GoP), a working group set up by the Commission, whose subsequent report laid the foundations of the European Defense Action Plan. At the meeting, a Commission civil servant said the goal of the group’s report was to “overcome resistance towards a defense research program.”
No Representation
GoP membership was heavily skewed towards the defense industry, with “barely any” independent voices represented, “let alone” critical voices such as peace groups or human rights organisations. The only member of the European Parliament that participated, center-right German Michael Gahler, is “known for his pro-military views” and a board member of a defense lobby organization.
Vredesactie noted the setting up of a Group of Personalities was “rare” and seems to have been deliberately used to evade “even basic levels of transparency” — the GoP was not registered as an expert group, and expert groups are to a certain extent subjected to rules regarding transparency (e.g. dates of meetings, agendas and minutes are publicly available).
“In the case of the GoP not even these basic rules were enforced. The reasons stated by the Commission for setting up the GoP have been inconsistent. The Commission at first declared the GoP is an expert group and therefore did not include any representatives from civil, but the Commission later denied [this], stating it provided political and strategic advice. In reality the GoP laid down the ideological foundation for the further militarization of Europe,” the report continued.
Disturbing Dynamic
The report concludes there is a “disturbing dynamic” going on at the EU level — what originally began life as a project to ensure continental peace between former perpetually-warring powers, has mutated into a bloc “subsidizing an industry which exports war.”
“The European Defense Fund creates a self-fulfilling and continuous loop between supply and demand, funded with public money. This creates the specter of a European permanent war economy, which has to be constantly funded by public means to remain competitive. The military technologies developed now, shape the wars of the future — the EU has already started developing autonomous systems through the Pilot Project and the Preparatory Action, despite warnings from both the scientific community as well as the European Parliament,” the report cautioned.
Furthermore, the disastrous impact of arms exports on the world has “not even [been] considered by European leaders,” instead viewed as a sign of a “thriving defense industrial base.” Modest calls for an upgrade of arms export control policies have not been heeded, and the European Defense Fund “will not lead to more security — because it is not meant to lead to more security.”
“The fund is an industrial stimulus fund for the major European arms-multinationals, located in only a few European countries. The undue influence of these companies at every level of the decision-making process has led to an outcome which solely takes economic considerations into account. This raises questions on the democratic legitimacy of these policies. Similarly, most Europeans are opposed to increased military expenditures and do not think ‘hard power’ is effective in combating terrorism,” the report concluded.
Busting Upward the Military Budget
By Ivan Eland | Consortium News | October 17, 2017
Although the Senate and House of Representatives have both passed the National Defense Authorization Act for fiscal year 2018 at the gargantuan sum of $700 billion, most of the largesse has little to do with defending the United States and much to do with policing the informal American overseas empire. Thus, at least some trimming to the huge amount is possible.
Of the $700 billion, about $640 billion is the Pentagon’s base budget and another $60 billion dollars is allocated to fight simultaneous wars in Afghanistan, Syria, Iraq and elsewhere. This whopping amount exceeds last year’s $619 billion, thus flouting the “sequestration” spending caps in the 2011 Budget Control Act. Trump and the Republicans want to use budget savings from domestic spending to finance the defense spending increases. However, they will need Democratic votes to break the sequestration caps; the Democrats’ price for doing so is a logrolling that would also require increases in domestic spending.
Yet the Budget Control Act has helped control federal spending, budget deficits, and debt accumulation and should be retained. Apparently, when conservatives tout slimming down government, they don’t seem to think the Defense Department is part of the federal bureaucracy.
The idea is preposterous that a country which alone accounts for about half the world’s defense budget needs more money to keep the readiness of its forces high and to rebuild a military that has been depleted by long, senseless wars in the Middle East and South Asia. The Defense Department is already slathered with over $600 billion a year and just needs to reallocate some of its funds to improve readiness and conduct rebuilding.
Yet members of Congress always propose amendments adding extra weapons systems, such as ships and aircraft, to the budget that the Defense Department doesn’t request. Not coincidentally, all this wasteful and unneeded pork spending just happens to be in these members’ home states. Such pork is a regular occurrence in defense budgeting and explains why the Defense budget is so massive, yet force readiness and equipment depletion remain problems.
Other wasteful spending perennially occurs on stateside military bases that even DoD would like to close, but members of Congress like to keep open because it subsidizes local economies they represent. The Pentagon offered a useful proposal that would have opened another round of base closures to save money. These savings could have been put toward readiness and rebuilding. Both the House and Senate rejected it for the aforementioned parochial reason.
Overseas Bases
To save even more money, the United States should close some overseas bases and decommission military units at those bases. Essentially, the military is like a fleet of expensive sports cars that is short on money for gas, repair, and maintenance. The overseas bases and forces need to be pruned so that the remaining forces at home have enough money for operations and support. With a $20 trillion debt, the United States is overextended in the world; the U.S. half of global defense spending is paid for out less than a quarter of the world’s GDP. Pruning the U.S. overseas footprint will help reduce the overextension.
Another way to save money would be to end unneeded and counterproductive wars in the Middle East and South Asia, which lead to increased blowback anti-U.S. terrorism. Sen. Rand Paul, R- Kentucky, laudably proposed repealing outdated congressional authorizations for the Afghanistan and Iraq Wars, passed in 2001 and 2002. Congress was so scared of the proposal that it didn’t even get a vote.
These two authorizations for the use of force should have been terminated. Going even further, one could question counterproductive (for the same reason as the Afghanistan and Iraq Wars), congressionally unapproved, and therefore unconstitutional air and drone wars in Pakistan, Somalia, Yemen, Syria, and Libya. Lives and even more money could be saved if they were also ended.
Therefore, eliminating pork spending, unneeded and counterproductive wars overseas, and excessive bases and forces at home and around the world could free up more money for military readiness and any post-war rebuilding necessary without ending the sequestration limits on defense spending needed to control budget deficits and debt accumulation, which are dragging the U.S. economy and preventing higher economic growth rates.
Ivan Eland is Senior Fellow and Director of the Center on Peace & Liberty at the Independent Institute.
DEA, Congress complicit in US opioid epidemic – whistleblowers
RT | October 16, 2017
The US Drug Enforcement Administration ‘shut off’ investigations into large distributors of addictive opioid pills, while a new law made it nearly impossible to prosecute them, the agency’s former employees said.
During the Obama administration, the drug industry used their money and influence to pressure top lawyers at the DEA to take a softer approach to investigating large distributors of opioid pills, even when there was ample evidence of suspicious dealings, Joe Rannazzisi, former head of the DEA’s Office of Diversion Control, told CBS’ 60 Minutes program.
Rannazzisi accused America’s largest painkiller distributors, including Cardinal Health, McKesson, and AmerisourceBergen, of “knowingly” turning a blind eye to the addictive pills being diverted to illicit use.
Former attorney at the DEA Jonathan Novak told CBS that in 2013 he also noticed a sea change in the way prosecutions of big distributors were handled, as his supervisors turned down cases they would have once easily approved. The DEA operates under the Department of Justice.
“These were not cases where it was black – where it was grey… These were cases where the evidence was crystal clear that there was wrongdoing going on,” Novak said.
Jim Geldhof, another former DEA investigator, told the program about a West Virginia case he was looking into where 11 million pills wound up in one of its counties with a population of just 25,000. He said he suddenly ran into roadblocks from one DEA supervisor.
“Every time I talked to this guy he wants something else. And I get it for him and that’s still not good enough,” Geldhof said. “And this goes on and on and on. When these roadblocks keep get thrown up in your face, at that point you know they just don’t want the case.”
“There was a lotta pills, a lotta people dying, and and we had tools in our toolbox to try to use and stem that flow. But it seemed down in headquarters that that toolbox was shut off,” said another former DEA official, Frank Younker.
The ex-employees said one of the reasons for the roadblocks was the “revolving door” between the DEA and the drug industry, as a number of the administration’s top lawyers landed lobbying jobs for the pharmaceutical companies and drug distributors upon leaving the government.
One such former DEA attorney wrote legislation which “made it all but impossible” to prosecute unscrupulous distributors, according to DEA chief administrative law judge, John J. Mulrooney.
The bill, called Ensuring Patient Access and Effective Drug Enforcement Act, was signed into law by president Obama last year, after it was passed by both chambers of Congress. Critics say it effectively stripped the DEA of its authority to investigate suspicious transactions as the government is now required to meet a higher standard before taking enforcement actions.
After Rannazzisi accused the bill’s co-sponsors Tom Marino (R-Pennsylvania) and Marsha Blackburn (R-Tennessee) of protecting distributors under his investigation, the lawmakers wrote the inspector general for the Justice Department, demanding that Rannazzisi be investigated for trying to “intimidate the United States Congress.”
Soon after, Rannazzisi was stripped of his responsibilities. He told CBS he went from supervising 600 people to supervising none – so he resigned.
Seven months after the bill became law, Marino’s chief of staff Bill Tighe became a lobbyist for the National Association of Chain Drug Stores.
Last month, President Donald Trump nominated Marino to lead the Office of National Drug Control Policy. In the wake of the 60 Minute investigation, some congressional Democrats called on the president to withdraw his nomination
Acting DEA chief Chuck Rosenberg, who led the agency under President Barack Obama, resigned at the end of September, reportedly over disagreements with Trump’s policies.
Prescription painkillers have stoked the epidemic of opioid overdoses and addictions across the US.
In August, Trump declared the opioid epidemic a national emergency after his Commission on Combating Drug Addiction and the Opioid Crisis reported that the US faces the death toll equal to “September 11th every three weeks” as the epidemic claims the lives of up to 142 Americans every day.
“60,000 Americans lost their lives to drug overdoses” in 2016, Attorney General Jeff Sessions said later that month.
“That will be the highest drug death toll and the fastest increase in that death toll in American history,” Session stated, adding that “this is not a sustainable trend nor an acceptable America.”
“80 percent of heroin addictions in America started with prescription drug addiction,” Sessions added, saying that the abuse of prescription drugs needs to be stopped.
Tossing bribery charges against Sen. Menendez to ‘decriminalize corruption’
Press TV – October 16, 2017
Prosecutors warn that tossing bribery charges against US Senator Robert Menendez – as being considered by a federal judge—would “decriminalize corruption” and “jettison the vast majority of bribery prosecutions.”
US District Judge William Walls suggested last week that the Justice Department’s bribery charges against Menendez may not move forward based on his reading of a 2016 Supreme Court opinion overturning the conviction of former Virginia Governor Bob McDonnell.
McDonnell had been convicted of corruption charges for taking gifts from a businessman in exchange for arranging a meeting between him and state officials.
In that ruling, the top court invalidated the “stream of benefits” theory of bribery that prosecutors have used to make legal cases against Menendez and other public officials.
“I know the prosecution had a heyday before McDonnell, and now they have a doomsday after McDonnell,” Walls said.
Federal prosecutors allege that Menendez accepted bribes from his co-defendant Salomon Melgen, a Florida ophthalmologist and longtime friend, in anticipation for the senator’s help “as opportunities arose” in the future.
Melgen has already been convicted in Florida for overbilling the Medicare program by millions of dollars, and faces a potentially lengthy prison sentence.
Prosecutors allege that Menendez intervened with federal agencies on Melgen’s behalf to resolve the billing dispute, to assist a $500 million port security contract, and to obtain US visas for Melgen’s girlfriends.
Menendez and Melgan have both denied the charges, with their attorneys arguing that what prosecutors call bribes were gifts exchanged between friends.
The high-profile case resumes Monday.
Both the Justice Department of defense attorneys filed motions during the weekend to bolster their arguments.
Prosecutors wrote that to dismiss charges against Menendez “would decriminalize the most egregious forms of corruption, incentivizing greedy businessmen to put politicians on retainer and immunizing lawmakers who solicit bribes in exchange for a promise to perform official acts.”
“The Supreme Court did not, and this Court should not, render a decision that has the unsettling effect of legalizing all such conduct.”
In total, the New Jersey Democrat faces six counts of bribery, three counts of honest services fraud, one count of conspiracy, one count of interstate travel to carry out bribery, and one count of making false statements on his congressional financial disclosures.
Pharmaceuticals can be a license to print money
By Pete Dolack | Systemic Disorder | October 11, 2107
It’s no secret that the United States suffers from by far the world’s highest costs for health care. As the most market-oriented health care system among advanced capitalist countries, this is no surprise. Health care in the U.S. is designed to deliver corporate profits, not health care.
On that score, the U.S. system is quite successful. Pharmaceutical companies are at the head of the class in this regard, frequently justifying the spiraling costs of medications by citing large research and development costs that include the costs for drugs that don’t make it to market. There are many drugs that fail to survive testing and become a cost that will never be compensated, that is true. But are these failures really so high to justify the extreme costs of successful drugs?
It would seem not. Firmer proof of that lack of justification has been published by the JAMA Internal Medicine journal, which found that revenue for cancer drugs far outstrips spending on research and development. The article, “Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval,” prepared by Drs. Vinay Prasad and Sham Mailankody, found that revenue from 10 drugs (one by each of 10 companies) exceed those companies’ total research and development costs by more than seven times.
The total revenue hauled in from these 10 drugs did vary considerably. Two of them earned more than US$20 billion after approval. Both of these high performers cost less than $500 million in research and development costs. The revenue from each of the 10, however, exceeded costs, with widely varied margins. Still profitable: The median revenue of these 10 drugs was $1.7 billion, more than double the median development cost of $648 million, the JAMA Internal Medicine authors report.
The authors write that the median cost to develop a cancer drug represents “a figure significantly lower than prior estimates,” adding that their analysis “provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing.”
To obtain these figures, the authors analyzed U.S. Securities and Exchange Commissions filings for pharmaceutical companies with no drugs on the U.S. market that received approval by the U.S. Food and Drug Administration for a cancer drug from January 1, 2006, through December 31, 2015. Cumulative R&D spending was estimated from initiation of drug development activity to date of approval. Earnings were tracked from the time of approval to March 2017.
The sky’s the limit for pharmaceutical prices

The increase in pharmaceutical prices (blue) versus the general increase in commodities prices (red).
Another way of looking at this would be to examine the increases in the cost of pharmaceuticals against other products. Here again the numbers stand out. Using data gathered by the St. Louis branch of the Federal Reserve Bank, the consumer price index for pharmaceutical preparation manufacturing for the first quarter of 2017 was 747.8, with January 1, 1980, as the benchmark of 100. In other words, the price of pharmaceuticals is seven and half times higher than they were at the start of 1980. (See graph above.)
How does that compare with inflation or other products? Quite well — for pharmaceutical companies. That more than sevenfold increase in drug prices is an increase nearly two and half times greater than inflation for the period, and nearly four times that of all commodities.
So, yes, unconscionable price-gouging is the cause here. By the industry as a whole, not simply individuals like “Pharma Bro” Martin Shkreli, who might be an outlier in his brazenness but not in his profit-generation plan.

Although not the entire picture, this snapshot of corporate extortion plays a significant role in why the cost of the United States not having a universal health care system is more than $1.4 trillion per year.
Among 19 broadly defined “major” industrial sectors in the U.S., health technology is again expected to be found the most profitable for 2016, with a profit margin of 21.6 percent. Higher even than finance at 17 percent. When narrowing to more specific, narrowly defined industry categories, generic pharmaceuticals sit at the top with an expected 30 percent profit margin for 2016. Major pharmaceuticals rank fourth at 25.5 percent on a list in which health products and finance claim nine of the top 10 spots.
The sky’s the limit for pharmaceutical profits
That’s a repeat of 2015, when health technology had the highest profit margin of 19 broadly defined industrial sectors, at 20.9 percent, topping even finance, the second highest. When a separate study broke down profit margins by more specific industry categories, health care-related industries comprised three of the six most profitable.
Nothing new there, either. A BBC report found that pharmaceuticals and banks tied for the highest average profit margin in 2013, with five pharmaceutical companies enjoying a profit margin of 20 percent or more — Pfizer, Hoffmann-La Roche, AbbVie, GlaxoSmithKline and Eli Lilly. The world’s 10 largest pharmaceutical corporations racked up a composite US$90 billion in profits for 2013, according to the BBC analysis. As to their expenses, these 10 firms spent far more on sales and marketing than they did on research and development.
If those facts and figures aren’t enough, here’s another way of looking at excessive profits — a 2015 study found that, of the 10 corporations that have the highest revenue per employee among the world’s biggest corporations, three are health care companies. Two of the three, Amerisourcebergen and McKesson, both distribute pharmaceuticals, and the other, Express Scrips, administers prescription drug benefits for tens of millions of health-plan members. Each of these primarily operates in the United States, the only advanced-capitalist country without universal health coverage.
The extra layers represented by those three companies demonstrate that there are ample opportunities for corporate profiteering that contribute to extraordinarily high health care costs in the U.S., beyond drug manufacturing and insurance.
And because corporations have the ear of politicians and other government officials, it’s no surprise that one of the primary ongoing goals of the U.S. government for so-called “free trade” agreements, such as the Trans-Pacific Partnership, is to impose rules that would weaken the national health care systems of other countries. This was done in TPP negotiations at the direct behest of U.S.-based pharmaceutical companies, incensed that countries like New Zealand make thousands of medicines, medical devices and related products available at subsidized costs.
By far the most expensive system while delivering among the worst outcomes and leaving tens of millions uninsured, where tens of thousands die from lack of health care annually. That is the high cost of private profit in health care. Or, to put it more bluntly, allowing the “market” to decide health outcomes instead of health care professionals.
Do you have hep C? Pharma hopes so
The sicker you get, the richer they become.
By Martha Rosenberg | Intrepid Report | October 13, 2017
The campaigns are everywhere. On ABC, NBC, CBS and FOX, Animal Planet, the Game Show Network and Syfy. In People, Popular Mechanics and Better Homes and Gardens magazines. On the radio and along subway lines. If you were born between 1945 and 1965, you could have hep C, screams Gilead Sciences, which makes the hep C drug Harvoni.
The campaign seeks to sound like a message from the Centers for Disease Control and Prevention addressing public health. But the Hepatitis C “facts” resulting from an Internet search are paid searches from Pharma, not from public health agencies.
Is there new information that shows baby boomers are newly prone to Hep C? Why have we not heard from the “CDC” about this pressing public health threat until now? There is new information—sales information that Gilead Hep C drugs are “plummeting” and new markets are needed.
“Gilead’s hep C blockbusters are in freefall, and its pool of eligible patients has shrunk dramatically thanks to the success of its meds,” says FiercePharma. “If all baby boomers got tested for the virus, though? That could help stem the tide—and it’s exactly the move the company is recommending with its latest awareness push.” Just trying to help.
David Johnson, Gilead VP, U.S. sales and marketing for liver diseases, admits the shameless disease mongering.
“This has been a planned evolution of our disease awareness efforts, to reach a much broader audience once the pool of already diagnosed patients who often had advanced disease and were in need of curative therapy, had been treated,” he says. “This staged approach was also important to ensure healthcare providers were equipped to support patients asking to be tested, as even for primary care providers, this disease was not something that was high on their radar due to the lack of scientific advances in the past to treat the disease.”
Only a handful of drug classes have been advertised more aggressively than hep C drugs, reports Stat News—drugs for erectile dysfunction and psoriasis “that afflict far more patients in the United States” than hepatitis C.
Hepatitis C drugs weigh in at $1,000 a pill—$84,000 for a course of treatment—and have been sacking the taxpayer-funded budgets of state Medicaid programs. States have considered suing over the heisting of their dollars and a Senate committee has looked at the price gouging. “If Gilead’s approach is the future of how blockbuster drugs are launched in America, it’s going to cost billions and billions of dollars to treat just a fraction of patients in America,” said Senator Ron Wyden, a Democrat from Oregon.
Congress is aware of the profiteering. The Senate’s Special Committee on Aging released a 130-page report revealing how “four pharmaceutical companies have taken advantage of our health care system to enrich themselves and their executives, harming patients and taxpayers,” according to the New York Times’ Gretchen Morgenson.
The chairwoman of the committee, Susan Collins, a Republican from Maine, and Claire McCaskill, a ranking member, Democrat from Missouri, say they have only begun to scratch the surface. They seek to “stop bad actors who are acquiring drugs that have been off-patent for decades and driving up their prices solely because they can,” they say.
Seeking to sell obscenely priced drugs paid for by the public’s dime to patients with no symptoms is bad enough. But the hep C meds are not even the wonder drugs they were billed as in the beginning. They were rolled out so fast to please Wall Street that Pharma did not know or care that patients with pre-existing, dormant hepatitis B infections could experience reactivation of the infections on the drugs and even die.
A year ago, the FDA found that 24 patients with pre-existing, dormant hepatitis B infections experienced reactivation of the infections while taking the hep C drugs. Two patients died and one required a liver transplant. The FDA promptly added boxed warnings on the hep C drug labels about the possible reactivation of hep B infections.
The Institute for Safe Medication Practices reported unintended liver effects with the aggressively marketed drugs. In one year, between June 2015 and June 2016, 165 people who took Sovaldi (an earlier drug) and Harvoni worldwide died, 524 had liver failure and 1,058 had severe liver injury. Could states have their money back?
Gilead’s unethical ads are halfway right. A terrible thing does happen if baby boomers don’t take its $1,000 a pill: Gilead makes no money.
Martha Rosenberg is a freelance journalist and the author of the highly acclaimed “Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health,” published by Prometheus Books.




















